NewEdge Advisors LLC Increases Stock Position in Intuitive Surgical, Inc. $ISRG

NewEdge Advisors LLC boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,825 shares of the medical equipment provider’s stock after acquiring an additional 8,142 shares during the quarter. NewEdge Advisors LLC’s holdings in Intuitive Surgical were worth $20,212,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ISRG. California State Teachers Retirement System raised its stake in shares of Intuitive Surgical by 39,531.1% in the second quarter. California State Teachers Retirement System now owns 213,725,958 shares of the medical equipment provider’s stock worth $84,994,539,000 after purchasing an additional 213,186,670 shares during the last quarter. State Street Corp boosted its position in shares of Intuitive Surgical by 1.0% during the fourth quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock valued at $8,892,753,000 after buying an additional 162,264 shares during the last quarter. Capital World Investors increased its holdings in Intuitive Surgical by 1.7% in the 4th quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock worth $4,449,491,000 after buying an additional 127,526 shares in the last quarter. Norges Bank bought a new stake in Intuitive Surgical in the 4th quarter worth about $2,856,987,000. Finally, Invesco Ltd. raised its position in Intuitive Surgical by 17.4% in the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock worth $2,338,350,000 after buying an additional 611,268 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on ISRG. Citigroup lowered their target price on shares of Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating on the stock in a research note on Friday, July 17th. Leerink Partners reduced their price target on shares of Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating for the company in a research note on Friday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Intuitive Surgical in a report on Friday, August 21st. Wall Street Zen downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Bank of America dropped their target price on shares of Intuitive Surgical from $520.00 to $515.00 in a report on Friday, June 12th. Twenty-two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $508.68.

Insider Buying and Selling

In other news, EVP Mark Brosius sold 77 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $375.57, for a total value of $28,918.89. Following the transaction, the executive vice president owned 881 shares of the company’s stock, valued at $330,877.17. This trade represents a 8.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy L. Ladd sold 400 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the transaction, the director directly owned 251 shares in the company, valued at $95,129. This trade represents a 61.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 11,256 shares of company stock valued at $4,475,079 over the last three months. 0.60% of the stock is currently owned by company insiders.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: A meta-analysis found that da Vinci robotic-assisted surgery produced statistically significant improvements across 13 common benign conditions, including shorter hospital stays and faster returns to work versus laparoscopic and open surgery. The results reinforce the clinical value of Intuitive’s platform and could support further hospital adoption. Intuitive reports positive meta-analysis data
• Positive Sentiment: BTIG reiterated its Buy rating and set a $469 price target, signaling considerable potential upside. Broader analyst coverage remains favorable, with the stock described as trading at its cheapest valuation in roughly a decade. Recent earnings also showed strong execution, including 18.4% year-over-year revenue growth and an earnings beat. BTIG reiterates Buy rating
• Neutral Sentiment: Intuitive Surgical presented at the Wells Fargo Healthcare Conference. Investors are focused on management’s commentary regarding procedure trends, guidance, competition, costs and the long-term opportunity for robotic surgery. Wells Fargo Healthcare Conference transcript
• Neutral Sentiment: Reported short-interest data showed zero shares and a zero-day short-interest ratio, suggesting no measurable short positioning in the supplied data; however, the figures appear anomalous and should not be treated as a meaningful trading signal.
• Negative Sentiment: EVP Mark Brosius disclosed sales totaling 69 shares at approximately $350.20 and $361.23 under a pre-arranged Rule 10b5-1 plan. The transactions are small relative to his remaining holdings and are not necessarily bearish, but continued insider selling provides little additional support for the shares. Intuitive Surgical EVP stock sale
• Negative Sentiment: Investors remain concerned about slower U.S. procedure growth, rising costs, competitive pressure and the possibility that GLP-1 drugs could affect procedure volumes. Options markets also indicate that substantial volatility may persist after the stock’s steep decline from its 52-week high. ISRG volatility outlook

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $360.46 on Friday. The company’s fifty day simple moving average is $377.41 and its 200-day simple moving average is $424.21. The stock has a market capitalization of $127.34 billion, a PE ratio of 41.29, a P/E/G ratio of 2.67 and a beta of 1.47. Intuitive Surgical, Inc. has a 1-year low of $328.57 and a 1-year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, topping the consensus estimate of $2.48 by $0.32. The firm had revenue of $2.89 billion during the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.Intuitive Surgical’s revenue was up 18.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.81 EPS. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 8.85 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc is a medical technology company that develops and manufactures robotic-assisted surgical systems and related products. Its technology is designed to support surgeons during minimally invasive procedures by providing enhanced visualization, instrument control and dexterity.

The company’s principal product is the da Vinci Surgical System, which is used across a range of specialties, including general surgery, urology, gynecology, cardiothoracic surgery and other procedures.